Lund B, Aabo K, Rørth M, Hansen H H
Eur J Cancer Clin Oncol. 1982 Nov;18(11):1089-92. doi: 10.1016/0277-5379(82)90088-8.
Thirty-eight previously treated patients with ovarian carcinoma received a combination of cis-dichlorodiammineplatinum (II) (CDDP) and hexamethylmelamine (HMM). The schedule was CDDP 75 mg/m2 i.v. with forced diuresis on day 1, followed by HMM 200 mg/m2 p.o. on days 8-21, repeated every 4 weeks. In 29 evaluable patients an overall response rate (CR + PR) of 35% with a median response duration of 4.5 months was observed. The performance status seemed to be an important prognostic factor. The gastrointestinal- and neurotoxicities were severe and resulted in dose modification and/or drug discontinuation in half of the patients. In conclusion, CDDP and HMM is an active drug combination in advanced ovarian carcinoma resistant to conventional chemotherapy. A possible superiority of this combination compared with CDDP or HMM alone has to await randomized trials.
38例既往接受过治疗的卵巢癌患者接受了顺二氯二氨铂（II）（CDDP）和六甲蜜胺（HMM）联合治疗。治疗方案为第1天静脉注射CDDP 75 mg/m²并强制利尿，随后在第8 - 21天口服HMM 200 mg/m²，每4周重复一次。在29例可评估患者中，观察到总缓解率（CR + PR）为35%，中位缓解持续时间为4.5个月。体能状态似乎是一个重要的预后因素。胃肠道和神经毒性严重，导致一半的患者出现剂量调整和/或停药。总之，CDDP和HMM是对传统化疗耐药的晚期卵巢癌的一种有效联合用药。与单独使用CDDP或HMM相比，这种联合用药的潜在优势有待随机试验验证。
